X
API Suppliers
0
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
0
Other Suppliers
0
0
0
USA (Orange Book)
0
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
USFDA Orange Book Patents
0
USFDA Exclusivities
0
Blog #PharmaFlow
0
News
EDQM
0
USP
0
JP
0
Other Listed Suppliers
0
0
Details:
Cedirogant (ABBV-157) is an orally available retinoic acid-related orphan receptor gamma (RORγ) inverse-agonist, small molecule for the treatment of chronic plaque psoriasis.
Lead Product(s): Cedirogant
Therapeutic Area: Dermatology Product Name: ABBV-157
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: AbbVie Inc
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Termination October 31, 2022
Details:
It follows the inclusion of the first patient with psoriasis in the ongoing Phase IIb clinical trial with cedirogant (ABBV-157), an oral RORγ inverse agonist jointly discovered by Inventiva and AbbVie for the treatment of autoimmune diseases.
Lead Product(s): Cedirogant
Therapeutic Area: Dermatology Product Name: ABBV-157
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: AbbVie Inc
Deal Size: $4.3 million Upfront Cash: Undisclosed
Deal Type: Collaboration January 31, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
